Stillwater Wealth Management Group Purchases 965 Shares of Amgen Inc. (NASDAQ:AMGN)

Stillwater Wealth Management Group raised its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 11.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,646 shares of the medical research company's stock after purchasing an additional 965 shares during the period. Amgen makes up approximately 2.6% of Stillwater Wealth Management Group's investment portfolio, making the stock its 17th biggest position. Stillwater Wealth Management Group's holdings in Amgen were worth $3,005,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Proficio Capital Partners LLC boosted its position in shares of Amgen by 35.0% during the 4th quarter. Proficio Capital Partners LLC now owns 1,806 shares of the medical research company's stock worth $471,000 after purchasing an additional 468 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Amgen by 89.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 54,176 shares of the medical research company's stock worth $14,120,000 after acquiring an additional 25,541 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Amgen by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 399,234 shares of the medical research company's stock worth $104,056,000 after acquiring an additional 11,878 shares during the last quarter. Finally, Impact Capital Partners LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $234,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Amgen stock traded down $4.52 during mid-day trading on Tuesday, reaching $292.51. The company's stock had a trading volume of 1,592,558 shares, compared to its average volume of 2,836,222. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a market capitalization of $157.28 billion, a P/E ratio of 26.69, a PEG ratio of 2.67 and a beta of 0.49. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. The firm's fifty day moving average price is $283.90 and its two-hundred day moving average price is $288.55.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same period in the previous year, the business earned $3.96 EPS. Amgen's revenue was up 9.4% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president directly owned 8,162 shares of the company's stock, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMGN. UBS Group restated a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a report on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Cantor Fitzgerald reiterated a "neutral" rating and issued a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Royal Bank Of Canada decreased their price objective on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen has an average rating of "Hold" and a consensus target price of $307.82.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.